Do analysts prefer IMA or ANEB?

ImageneBio presently has a consensus target price of $29.00, indicating a potential upside of 438.03%. Given ImageneBio's stronger consensus rating and higher possible upside, equities analysts plainly believe ImageneBio is more favorable than Anebulo Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImageneBio 2 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.20 Anebulo Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is IMA or ANEB more profitable?

ImageneBio's return on equity of -38.99% beat Anebulo Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets ImageneBio N/A -38.99% -34.84% Anebulo Pharmaceuticals N/A -74.57% -68.96%

Do analysts prefer ANEB or MCRB?

Seres Therapeutics has a consensus price target of $17.00, suggesting a potential upside of 235.97%. Given Seres Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Seres Therapeutics is more favorable than Anebulo Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anebulo Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Seres Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Do analysts rate ANVS or ANEB?

Annovis Bio presently has a consensus target price of $12.00, indicating a potential upside of 976.23%. Given Annovis Bio's stronger consensus rating and higher probable upside, equities analysts plainly believe Annovis Bio is more favorable than Anebulo Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Annovis Bio 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Anebulo Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation & earnings, ANVS or ANEB?

Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Annovis Bio N/A N/A -$28.85M -$1.79 N/A Anebulo Pharmaceuticals N/A N/A -$8.48M -$0.19 N/A

Is ANVS or ANEB more profitable?

Anebulo Pharmaceuticals' return on equity of -74.57% beat Annovis Bio's return on equity. Company Net Margins Return on Equity Return on Assets Annovis Bio N/A -685.98% -258.77% Anebulo Pharmaceuticals N/A -74.57% -68.96%

Do analysts prefer APLM or ANEB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Anebulo Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, APLM or ANEB?

Anebulo Pharmaceuticals has lower revenue, but higher earnings than Apollomics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Apollomics $8.50M 6.12 -$10.94M N/A N/A Anebulo Pharmaceuticals N/A N/A -$8.48M -$0.19 N/A

Is APLM or ANEB more profitable?

Apollomics' return on equity of 0.00% beat Anebulo Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Apollomics N/A N/A N/A Anebulo Pharmaceuticals N/A -74.57% -68.96%

Do analysts prefer IMMP or ANEB?

Prima BioMed currently has a consensus target price of $5.50, suggesting a potential upside of 1,532.05%. Given Prima BioMed's stronger consensus rating and higher possible upside, research analysts clearly believe Prima BioMed is more favorable than Anebulo Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prima BioMed 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Anebulo Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, IMMP or ANEB?

Anebulo Pharmaceuticals has lower revenue, but higher earnings than Prima BioMed. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Prima BioMed $16.40M 3.03 -$53.82M N/A N/A Anebulo Pharmaceuticals N/A N/A -$8.48M -$0.19 N/A

Is IMMP or ANEB more profitable?

Prima BioMed's return on equity of 0.00% beat Anebulo Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Prima BioMed N/A N/A N/A Anebulo Pharmaceuticals N/A -74.57% -68.96%

Anebulo Pharmaceuticals (ANEB) Competitors

$0.33 0.00 (0.00%)

As of 09/11/2026 09:34 AM Eastern

Compare

ANEB vs. IMA, MCRB, ANVS, APLM, and IMMP

Should you buy Anebulo Pharmaceuticals stock or one of its competitors? Anebulo Pharmaceuticals's main competitors and comparable companies include ImageneBio (IMA), Seres Therapeutics (MCRB), Annovis Bio (ANVS), Apollomics (APLM), and Prima BioMed (IMMP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Anebulo Pharmaceuticals compare to ImageneBio?

ImageneBio (NASDAQ:IMA) and Anebulo Pharmaceuticals (NASDAQ:ANEB) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings.

75.0% of ImageneBio shares are owned by institutional investors. Comparatively, 28.4% of Anebulo Pharmaceuticals shares are owned by institutional investors. 2.2% of ImageneBio shares are owned by insiders. Comparatively, 80.6% of Anebulo Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

ImageneBio has a beta of 0.7, meaning that its share price is 30% less volatile than the broader market. Comparatively, Anebulo Pharmaceuticals has a beta of -1.82, meaning that its share price is 282% less volatile than the broader market.

In the previous week, ImageneBio had 4 more articles in the media than Anebulo Pharmaceuticals. MarketBeat recorded 4 mentions for ImageneBio and 0 mentions for Anebulo Pharmaceuticals. ImageneBio's average media sentiment score of 0.47 beat Anebulo Pharmaceuticals' score of 0.00 indicating that ImageneBio is being referred to more favorably in the media.

Company	Overall Sentiment
ImageneBio	Neutral
Anebulo Pharmaceuticals	Neutral

ImageneBio presently has a consensus target price of $29.00, indicating a potential upside of 438.03%. Given ImageneBio's stronger consensus rating and higher possible upside, equities analysts plainly believe ImageneBio is more favorable than Anebulo Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImageneBio	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.20
Anebulo Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Anebulo Pharmaceuticals has lower revenue, but higher earnings than ImageneBio. Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than ImageneBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImageneBio	$800K	76.47	-$45.35M	-$4.58	N/A
Anebulo Pharmaceuticals	N/A	N/A	-$8.48M	-$0.19	N/A

ImageneBio's return on equity of -38.99% beat Anebulo Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImageneBio	N/A	-38.99%	-34.84%
Anebulo Pharmaceuticals	N/A	-74.57%	-68.96%

Summary

ImageneBio beats Anebulo Pharmaceuticals on 12 of the 15 factors compared between the two stocks.

How does Anebulo Pharmaceuticals compare to Seres Therapeutics?

Anebulo Pharmaceuticals (NASDAQ:ANEB) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability.

Anebulo Pharmaceuticals has a beta of -1.82, meaning that its stock price is 282% less volatile than the broader market. Comparatively, Seres Therapeutics has a beta of 0.21, meaning that its stock price is 79% less volatile than the broader market.

In the previous week, Seres Therapeutics had 2 more articles in the media than Anebulo Pharmaceuticals. MarketBeat recorded 2 mentions for Seres Therapeutics and 0 mentions for Anebulo Pharmaceuticals. Seres Therapeutics' average media sentiment score of 0.93 beat Anebulo Pharmaceuticals' score of 0.00 indicating that Seres Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Anebulo Pharmaceuticals	Neutral
Seres Therapeutics	Positive

Seres Therapeutics has a consensus price target of $17.00, suggesting a potential upside of 235.97%. Given Seres Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Seres Therapeutics is more favorable than Anebulo Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anebulo Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Seres Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Seres Therapeutics has higher revenue and earnings than Anebulo Pharmaceuticals. Seres Therapeutics is trading at a lower price-to-earnings ratio than Anebulo Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anebulo Pharmaceuticals	N/A	N/A	-$8.48M	-$0.19	N/A
Seres Therapeutics	$790K	64.37	$5.70M	-$2.43	N/A

28.4% of Anebulo Pharmaceuticals shares are held by institutional investors. Comparatively, 59.3% of Seres Therapeutics shares are held by institutional investors. 80.6% of Anebulo Pharmaceuticals shares are held by insiders. Comparatively, 5.2% of Seres Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Anebulo Pharmaceuticals has a net margin of 0.00% compared to Seres Therapeutics' net margin of -1,192.94%. Anebulo Pharmaceuticals' return on equity of -74.57% beat Seres Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anebulo Pharmaceuticals	N/A	-74.57%	-68.96%
Seres Therapeutics	-1,192.94%	-114.82%	-34.15%

Summary

Seres Therapeutics beats Anebulo Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Anebulo Pharmaceuticals compare to Annovis Bio?

Annovis Bio (NYSE:ANVS) and Anebulo Pharmaceuticals (NASDAQ:ANEB) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.

Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annovis Bio	N/A	N/A	-$28.85M	-$1.79	N/A
Anebulo Pharmaceuticals	N/A	N/A	-$8.48M	-$0.19	N/A

In the previous week, Annovis Bio had 2 more articles in the media than Anebulo Pharmaceuticals. MarketBeat recorded 2 mentions for Annovis Bio and 0 mentions for Anebulo Pharmaceuticals. Annovis Bio's average media sentiment score of 0.51 beat Anebulo Pharmaceuticals' score of 0.00 indicating that Annovis Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Annovis Bio	Positive
Anebulo Pharmaceuticals	Neutral

Annovis Bio presently has a consensus target price of $12.00, indicating a potential upside of 976.23%. Given Annovis Bio's stronger consensus rating and higher probable upside, equities analysts plainly believe Annovis Bio is more favorable than Anebulo Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Anebulo Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Annovis Bio has a beta of 1.24, meaning that its stock price is 24% more volatile than the broader market. Comparatively, Anebulo Pharmaceuticals has a beta of -1.82, meaning that its stock price is 282% less volatile than the broader market.

Anebulo Pharmaceuticals' return on equity of -74.57% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annovis Bio	N/A	-685.98%	-258.77%
Anebulo Pharmaceuticals	N/A	-74.57%	-68.96%

15.8% of Annovis Bio shares are owned by institutional investors. Comparatively, 28.4% of Anebulo Pharmaceuticals shares are owned by institutional investors. 20.8% of Annovis Bio shares are owned by insiders. Comparatively, 80.6% of Anebulo Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Annovis Bio beats Anebulo Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Anebulo Pharmaceuticals compare to Apollomics?

Apollomics (NASDAQ:APLM) and Anebulo Pharmaceuticals (NASDAQ:ANEB) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings, media sentiment and analyst recommendations.

19.1% of Apollomics shares are owned by institutional investors. Comparatively, 28.4% of Anebulo Pharmaceuticals shares are owned by institutional investors. 80.6% of Anebulo Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Apollomics has a beta of 1.53, indicating that its stock price is 53% more volatile than the broader market. Comparatively, Anebulo Pharmaceuticals has a beta of -1.82, indicating that its stock price is 282% less volatile than the broader market.

Apollomics' return on equity of 0.00% beat Anebulo Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apollomics	N/A	N/A	N/A
Anebulo Pharmaceuticals	N/A	-74.57%	-68.96%

Anebulo Pharmaceuticals has lower revenue, but higher earnings than Apollomics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apollomics	$8.50M	6.12	-$10.94M	N/A	N/A
Anebulo Pharmaceuticals	N/A	N/A	-$8.48M	-$0.19	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Anebulo Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Apollomics had 1 more articles in the media than Anebulo Pharmaceuticals. MarketBeat recorded 1 mentions for Apollomics and 0 mentions for Anebulo Pharmaceuticals. Apollomics' average media sentiment score of 1.89 beat Anebulo Pharmaceuticals' score of 0.00 indicating that Apollomics is being referred to more favorably in the media.

Company	Overall Sentiment
Apollomics	Very Positive
Anebulo Pharmaceuticals	Neutral

Summary

Apollomics beats Anebulo Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

How does Anebulo Pharmaceuticals compare to Prima BioMed?

Prima BioMed (NASDAQ:IMMP) and Anebulo Pharmaceuticals (NASDAQ:ANEB) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, valuation, earnings, dividends, analyst recommendations and risk.

Prima BioMed has a beta of 2.21, indicating that its stock price is 121% more volatile than the broader market. Comparatively, Anebulo Pharmaceuticals has a beta of -1.82, indicating that its stock price is 282% less volatile than the broader market.

Prima BioMed currently has a consensus target price of $5.50, suggesting a potential upside of 1,532.05%. Given Prima BioMed's stronger consensus rating and higher possible upside, research analysts clearly believe Prima BioMed is more favorable than Anebulo Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prima BioMed	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Anebulo Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Anebulo Pharmaceuticals has lower revenue, but higher earnings than Prima BioMed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prima BioMed	$16.40M	3.03	-$53.82M	N/A	N/A
Anebulo Pharmaceuticals	N/A	N/A	-$8.48M	-$0.19	N/A

Prima BioMed's return on equity of 0.00% beat Anebulo Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prima BioMed	N/A	N/A	N/A
Anebulo Pharmaceuticals	N/A	-74.57%	-68.96%

2.3% of Prima BioMed shares are owned by institutional investors. Comparatively, 28.4% of Anebulo Pharmaceuticals shares are owned by institutional investors. 3.1% of Prima BioMed shares are owned by insiders. Comparatively, 80.6% of Anebulo Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Prima BioMed had 3 more articles in the media than Anebulo Pharmaceuticals. MarketBeat recorded 3 mentions for Prima BioMed and 0 mentions for Anebulo Pharmaceuticals. Anebulo Pharmaceuticals' average media sentiment score of 0.00 beat Prima BioMed's score of -0.04 indicating that Anebulo Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Prima BioMed	Neutral
Anebulo Pharmaceuticals	Neutral

Summary

Prima BioMed beats Anebulo Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

Get Anebulo Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANEB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANEB vs. The Competition

Export

Metric	Anebulo Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$13.52M	$3.84B	$7.15B	$12.84B
Dividend Yield	N/A	3.66%	2.57%	11.71%
P/E Ratio	-1.74	14.25	275.28	25.35
Price / Sales	N/A	1,418.81	646.14	90.72
Price / Cash	N/A	43.64	28.42	34.96
Price / Book	1.18	15.23	10.37	6.21
Net Income	-$8.48M	-$22.86M	$3.50B	$358.54M
7 Day Performance	-7.56%	-4.37%	-3.30%	-2.39%
1 Month Performance	3.59%	-0.66%	-0.86%	-3.39%
1 Year Performance	-86.01%	40.76%	23.53%	8.81%

Anebulo Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANEB Anebulo Pharmaceuticals	N/A	$0.33 flat	N/A	-86.0%	$13.52M	N/A	N/A	4
IMA ImageneBio	3.0488 of 5 stars	$5.01 -0.8%	$29.00 +478.8%	-44.4%	$57.33M	$800K	N/A	70
MCRB Seres Therapeutics	2.7826 of 5 stars	$5.28 -5.0%	$17.00 +222.0%	-68.5%	$55.85M	$790K	N/A	330	Gap Up
ANVS Annovis Bio	2.2621 of 5 stars	$1.23 -5.5%	$12.00 +877.2%	-54.8%	$55.39M	N/A	N/A	3	Analyst Downgrade
APLM Apollomics	2.1082 of 5 stars	$24.39 -0.4%	N/A	+240.4%	$53.80M	$8.50M	N/A	45	Positive News Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ANEB) was last updated on 9/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Anebulo Pharmaceuticals (ANEB) Competitors

ANEB vs. IMA, MCRB, ANVS, APLM, and IMMP

How does Anebulo Pharmaceuticals compare to ImageneBio?

Summary

How does Anebulo Pharmaceuticals compare to Seres Therapeutics?

Summary

How does Anebulo Pharmaceuticals compare to Annovis Bio?

Summary

How does Anebulo Pharmaceuticals compare to Apollomics?

Summary

How does Anebulo Pharmaceuticals compare to Prima BioMed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANEB vs. The Competition

Anebulo Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Anebulo Pharmaceuticals (ANEB) Competitors

ANEB vs. IMA, MCRB, ANVS, APLM, and IMMP

How does Anebulo Pharmaceuticals compare to ImageneBio?

Do insiders and institutionals hold more shares of IMA or ANEB?

Which has more risk and volatility, IMA or ANEB?

Does the media refer more to IMA or ANEB?

Do analysts prefer IMA or ANEB?

Which has higher valuation & earnings, IMA or ANEB?

Is IMA or ANEB more profitable?

Summary

How does Anebulo Pharmaceuticals compare to Seres Therapeutics?

Which has more risk and volatility, ANEB or MCRB?

Does the media refer more to ANEB or MCRB?

Do analysts prefer ANEB or MCRB?

Which has higher valuation & earnings, ANEB or MCRB?

Do institutionals & insiders hold more shares of ANEB or MCRB?

Is ANEB or MCRB more profitable?

Summary

How does Anebulo Pharmaceuticals compare to Annovis Bio?

Which has better valuation & earnings, ANVS or ANEB?

Does the media refer more to ANVS or ANEB?

Do analysts rate ANVS or ANEB?

Which has more risk & volatility, ANVS or ANEB?

Is ANVS or ANEB more profitable?

Do institutionals and insiders have more ownership in ANVS or ANEB?

Summary

How does Anebulo Pharmaceuticals compare to Apollomics?

Do institutionals and insiders hold more shares of APLM or ANEB?

Which has more risk and volatility, APLM or ANEB?

Is APLM or ANEB more profitable?

Which has higher valuation and earnings, APLM or ANEB?

Do analysts prefer APLM or ANEB?

Does the media refer more to APLM or ANEB?

Summary

How does Anebulo Pharmaceuticals compare to Prima BioMed?

Which has more volatility and risk, IMMP or ANEB?

Do analysts prefer IMMP or ANEB?

Which has stronger earnings & valuation, IMMP or ANEB?

Is IMMP or ANEB more profitable?

Do institutionals & insiders hold more shares of IMMP or ANEB?

Does the media refer more to IMMP or ANEB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANEB vs. The Competition

Anebulo Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools